Project Grant R21TR004938
Award Date
6/1/24
Completion Date
5/31/26
Dollars Obligated
$110K
Federal Agency
National Center for Advancing Translational Sciences
Federal Grant Program
93.350
Assistance Type
Project Grant
Place of Performance
Palo Alto, CA 94304, USA
Similar Awards
The federal Project Grant award of $1,348,274.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) is supporting research by Greenstone Biosciences, Inc. to elucidate the mechanistic pathways of LMNA cardiomyopathy and identify novel therapeutic compounds. The funding period runs from May 15, 2024 to May 14, 2028. Greenstone Biosciences, a biotechnology company in Palo Alto, California, is leveraging advanced drug discovery and development...
The Project Grant award of $490,000.00 from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program supports Greenstone Biosciences, Inc.'s research into drug discovery for Duchenne muscular dystrophy using artificial intelligence, machine learning, and induced pluripotent stem cell-derived organoids. The award, which runs from September 30, 2024 to September 29, 2026, will enable the company to leverage its expertise in computational...
This Project Grant award from the National Institutes of Health (NIH) Office of the Director, under the Trans-NIH Research Support program (CFDA 93.310), provides $337,999 to the Icahn School of Medicine at Mount Sinai to conduct research on identifying potential drug repurposing candidates for rare genetic diseases. The research aims to leverage large genomic datasets from NIH Common Fund programs to computationally predict gain-of-function genetic variants that could be targeted by existing...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant of $274,829 awarded to Rosebud Biosciences Inc. on August 15, 2023 aims to enable the development of new therapies for rare diseases in children. The project objectives are to: (1) Automate the derivation of heart, liver, and brain organoids from human stem cells, and (2) Develop automated machine learning models to detect disease phenotypes in these organoids derived from patients with...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Foragr Medicines, Inc. aims to develop a high-throughput platform for using small molecules to target the messenger RNAs (mRNAs) of previously "undruggable" proteins. The platform will enable efficient and cost-effective screening of small molecule drugs that can modulate disease-related mRNAs, opening up new therapeutic opportunities for hard-to-treat...
This $387,579 federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) aims to advance computational modeling of disease metabolism by integrating artificial intelligence (AI) and systems biology approaches. The grant supports the development of a suite of computational tools, including a data-driven research framework, dynamic metabolic models, statistical metrics, and natural language...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support the development of an AI-based platform to accelerate the discovery of new therapeutic options for substance use disorders (SUDs). The $397,829 award will enable the awardee, Callentis Consulting Group LLC, to leverage machine learning models and graph neural networks to identify potential targets and compounds that can modulate reward system...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) is focused on developing innovative machine learning-based predictive models to accurately identify cured or uncured disease status in patients, particularly for early-stage diseases. The $278,104 award, which runs from May 1, 2025 to April 30, 2030, aims to address key limitations of existing predictive models by creating biologically...
This $500,000 Project Grant was awarded by the National Institute on Aging under the Aging Research federal grant program (CFDA 93.866) to Neucyte Inc., a minority-owned small business. The funding supports the development of a nanoluciferase-based microphysiological systems (MPS) platform to enable high-throughput screening of potential Alzheimer's disease (AD) and AD-related dementia (ADRD) therapeutics. Neucyte will leverage human induced pluripotent stem cell technology to create scalable,...
This federal Project Grant award from the National Center for Advancing Translational Sciences (NCATS), CFDA 93.350, provides $110,000 to Myogene Bio LLC to conduct preclinical research on the long-term durability of a gene editing therapy for Duchenne muscular dystrophy (DMD). The gene editing therapy is designed to remove DMD exons 45-55 to restore the reading frame for 50% of DMD patients while retaining 87% of the protein coding sequence. The funded studies will assess molecular and...